Delos Capital

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

AltruBio is a biopharmaceutical company focused on developing targeted antibody therapeutics for cancer and immune-related inflammatory diseases. Established in Delaware with its principal office in the San Francisco Bay Area, AltruBio integrates global resources to advance its research and development initiatives. The company has its roots in Taipei, Taiwan, where it has been working since June 2000 on discovering and developing novel therapeutics to address unmet medical needs. AltruBio employs a sophisticated discovery platform to identify and validate new antibody therapeutics. Currently, the company is developing several potential therapeutic antibodies that target a range of conditions, including autoimmune diseases and various types of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancers, at different stages of development.

Avenzo Therapeutics is a clinical-stage company focused on developing innovative oncology therapies aimed at treating cancer. The company’s platform is dedicated to creating novel treatments specifically for underserved cancers, including rare and genomically defined types. By advancing a pipeline of targeted drug candidates, Avenzo Therapeutics seeks to enhance treatment options for both researchers and patients, addressing significant gaps in current cancer care.

Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases.

Instylla is a Bedford, Massachusetts-based medical equipment supplier specializing in next-generation liquid embolics for interventional radiology. The company focuses on developing innovative embolization products that enhance patient outcomes, particularly in applications such as peripheral hemostasis and interventional oncology. Its flagship product, the Embrace Hydrogel Embolic System, is designed to facilitate controlled, complete, and persistent embolization, providing healthcare professionals with advanced tools for effective treatment in various clinical scenarios.

Eccogene is a clinical stage biopharmaceutical company focused on developing therapeutic solutions for unmet medical needs, particularly in the areas of metabolism and immune-related diseases. The company specializes in disease biology, medicinal chemistry, and translational science, aiming to create immunological pharmaceuticals at the molecular level to address complex chronic conditions such as obesity and diabetes. Through its innovative approach, Eccogene is building a pipeline of metabolic drugs designed to enhance patient outcomes and improve health conditions related to these chronic diseases.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Le Sueur is a mining and metals company that specializes in the production of complex and pressure-tight aluminum castings and plastic injection molding components. The company serves various markets, including rail, specialty automotive, and electric vehicles. Utilizing a range of manufacturing processes such as permanent mold, sand casting, die casting, and precision machining, Le Sueur ensures high-quality production while providing engineering support services to its clients. Their focus on affordable manufacturing methods allows them to meet the diverse needs of their customers effectively.

Rejoni, Inc. is a medical device company specializing in gynecological surgical procedures, focusing on the development and commercialization of products that reduce the risk of scar formation after intrauterine interventions. Founded in 2020 and based in Bedford, Massachusetts, Rejoni aims to enhance the outcomes of both minimally invasive and traditional gynecological surgeries. By utilizing biomaterials, the company seeks to address both acute and chronic risks associated with these procedures, ultimately providing women with technologies that support their overall health and well-being.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

Ostial Corporation, founded in 2008 and based in Campbell, California, specializes in developing catheter-based delivery systems aimed at addressing the challenges associated with aorto-ostial stenting. The company’s flagship product, The FLASH Aorto-Ostial System, features a dual-balloon angioplasty catheter designed to stabilize and conform the stent to the ostium during post-dilation and angioplasty procedures. This innovative system enables physicians to achieve optimal stent wall apposition after post-dilation, enhancing patient outcomes and facilitating easier vessel reaccess. Ostial Corporation's products are applicable for both coronary and peripheral medical indications.

Exela Technologies is a leader in business process automation (BPA), offering a range of enterprise software and solutions tailored for specific industries as well as general applications. The company serves vital sectors such as banking, healthcare, and insurance, providing solutions that enhance operational efficiency in mission-critical environments. Exela's BPA suite includes workflow automation, cognitive automation, digital mailrooms, print communications, and payment processing, demonstrating its capability to streamline complex processes. The company operates through various segments, notably Information and Transaction Processing Solutions, which is its primary revenue source, along with Healthcare Solutions and Legal and Loss Prevention Services. With a global presence, Exela Technologies leverages its extensive experience to meet the evolving needs of its clients across multiple industries.

United Flea Markets is a company based in Henderson, Colorado, that manages and operates various outdoor shopping and entertainment events, including flea markets and farmers' markets. The organization provides a platform for small businesses by offering a diverse range of indoor and outdoor market spaces, as well as event pavilions and open lots. Their markets feature a wide assortment of products, live music, food options, and in some locations, adult beverages. By creating vibrant community spaces, United Flea Markets supports local entrepreneurs and fosters a unique shopping experience for consumers.

Pioneer Recycling Services, LLC operates recycling plants in Tacoma, Washington, and Clackamas, Oregon, specializing in non-hazardous recycling and solid waste management. The company serves a diverse clientele, including commercial, industrial, municipal, and residential customers, by providing reliable environmental services and solutions. Annually, Pioneer processes over 200,000 tons of recyclable materials across its facilities, making it one of the largest Material Recycling Facilities in the Pacific Northwest. The company offers a range of waste processing services, which include sorting comingled office recyclables as well as grade-separated recyclables, thereby helping clients minimize waste and maximize the reusability of materials.

Viron is a biopharmaceutical company focused on developing innovative therapies aimed at addressing a range of serious health conditions, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Utilizing advanced technologies such as genomics, gene editing, stem cell biology, and artificial intelligence, Viron aims to identify and create high-value therapies targeting specific protein and lipid pathways. The company's approach emphasizes the use of patient-derived organoids and high-throughput screening methods to enhance drug discovery. By leveraging these breakthroughs, Viron seeks to transform treatment paradigms and improve patient outcomes in various diseases.

Viron is a biopharmaceutical company focused on developing innovative therapies aimed at addressing a range of serious health conditions, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Utilizing advanced technologies such as genomics, gene editing, stem cell biology, and artificial intelligence, Viron aims to identify and create high-value therapies targeting specific protein and lipid pathways. The company's approach emphasizes the use of patient-derived organoids and high-throughput screening methods to enhance drug discovery. By leveraging these breakthroughs, Viron seeks to transform treatment paradigms and improve patient outcomes in various diseases.

MechanAir is a collective of regional businesses specializing in mechanical services, HVAC systems, and plumbing. The company operates as a platform for commercial contractors in these fields, focusing on delivering complex and value-added engineering solutions. With a presence across the Midwest and East Coast, MechanAir differentiates itself through its diverse industry expertise and technological capabilities, ensuring that clients receive tailored services to meet their specific needs.

Imperative Care, Inc. is dedicated to enhancing the speed and effectiveness of acute stroke treatment through innovative medical technologies. Founded in 2015 and based in Campbell, California, the company has developed a range of solutions aimed at addressing critical needs in stroke care. Among its offerings is the Large Distal Platform, a large diameter catheter designed to reach treatment sites for both ischemic and hemorrhagic strokes. Complementing this is the ZOOM Aspiration System, a comprehensive solution that works in conjunction with the Large Distal Platform and includes various trackable reperfusion catheters for effective clot removal. By advancing stroke treatment technologies, Imperative Care aims to improve patient outcomes and optimize recovery processes for those affected by strokes.

Phanes Therapeutics, Inc. is a biotechnology company based in San Diego, California, established in 2016. The company specializes in drug discovery and early development, primarily in the fields of immuno-oncology and eye diseases. Phanes Therapeutics is developing a range of therapeutic molecules, including a monoclonal antibody aimed at treating solid tumors, as well as therapies for age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Additionally, the company is working on bispecific antibodies targeting small cell lung cancer. Through its extensive scientific expertise and innovative approaches, Phanes Therapeutics aims to create effective treatment options that enhance patient care and improve outcomes for those suffering from various conditions.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.

Clover Biopharmaceuticals is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative biologic therapies primarily targeting oncology and autoimmune diseases. The company employs its proprietary Trimer-Tag technology platform to create novel biologics that focus on trimerization-dependent pathways. In addition to its therapeutic efforts, Clover is also engaged in the development of select biosimilars, utilizing its in-house cGMP biomanufacturing capabilities. The company aims to address unmet medical needs in both infectious diseases and cancer through its advanced vaccine and therapeutic candidates.

Rejoni, Inc. is a medical device company specializing in gynecological surgical procedures, focusing on the development and commercialization of products that reduce the risk of scar formation after intrauterine interventions. Founded in 2020 and based in Bedford, Massachusetts, Rejoni aims to enhance the outcomes of both minimally invasive and traditional gynecological surgeries. By utilizing biomaterials, the company seeks to address both acute and chronic risks associated with these procedures, ultimately providing women with technologies that support their overall health and well-being.

Imperative Care, Inc. is dedicated to enhancing the speed and effectiveness of acute stroke treatment through innovative medical technologies. Founded in 2015 and based in Campbell, California, the company has developed a range of solutions aimed at addressing critical needs in stroke care. Among its offerings is the Large Distal Platform, a large diameter catheter designed to reach treatment sites for both ischemic and hemorrhagic strokes. Complementing this is the ZOOM Aspiration System, a comprehensive solution that works in conjunction with the Large Distal Platform and includes various trackable reperfusion catheters for effective clot removal. By advancing stroke treatment technologies, Imperative Care aims to improve patient outcomes and optimize recovery processes for those affected by strokes.

Clover Biopharmaceuticals is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative biologic therapies primarily targeting oncology and autoimmune diseases. The company employs its proprietary Trimer-Tag technology platform to create novel biologics that focus on trimerization-dependent pathways. In addition to its therapeutic efforts, Clover is also engaged in the development of select biosimilars, utilizing its in-house cGMP biomanufacturing capabilities. The company aims to address unmet medical needs in both infectious diseases and cancer through its advanced vaccine and therapeutic candidates.

Curamir is a Woburn, MA-based biotechnology company launched and incubated by Delos Capital with an initial academic licensing from SUNY. Through its proprietary miRNA engineering platform and insights into cancer biology, Curamir develops miRNA-based cancer therapeutics with enhanced safety, potency and stability. Its novel approach addresses current challenges associated with both chemoresistance in cancer and effective systemic delivery of miRNA mimics.

Viron is a biopharmaceutical company focused on developing innovative therapies aimed at addressing a range of serious health conditions, including cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Utilizing advanced technologies such as genomics, gene editing, stem cell biology, and artificial intelligence, Viron aims to identify and create high-value therapies targeting specific protein and lipid pathways. The company's approach emphasizes the use of patient-derived organoids and high-throughput screening methods to enhance drug discovery. By leveraging these breakthroughs, Viron seeks to transform treatment paradigms and improve patient outcomes in various diseases.

Barricaid is a medical device company that focuses on developing innovative solutions to prevent repeat disc herniation in patients who have undergone back surgery. The company's flagship product is a bone-anchored implant designed to reduce the likelihood of reherniation and the need for reoperation in cases involving large annular defects. This implant physically blocks the annulus at the surgical defect, enhancing the surgical outcome for patients at high risk of complications after lumbar discectomy. Composed of a titanium alloy, the device securely anchors into the vertebral body, either caudally or cranially, ensuring stability and effectiveness. By addressing the challenges associated with post-surgical recovery, Barricaid aims to improve patient outcomes and reduce the incidence of further surgeries related to sciatica.

Antios Therapeutics, Inc. is a biopharmaceutical company based in Atlanta, Georgia, founded in 2018. The company focuses on developing innovative therapies for viral diseases, particularly through its oral drug candidate, ATI-2173, aimed at treating patients infected with Hepatitis B and Hepatitis D viruses. With a leadership team that possesses extensive experience in the field, Antios Therapeutics is dedicated to advancing its research and development efforts toward potentially curative treatments for Hepatitis B virus infections.

HOP Energy, LLC is a full-service energy company that offers a variety of residential and commercial energy solutions throughout the northeastern United States. Founded in 1995 and headquartered in White Plains, New York, the company provides residential customers with heating oils, propane fuel and tanks, and a range of heating and cooling equipment, alongside 24-hour service and comprehensive service contracts for essential appliances such as water heaters and humidifiers. For commercial clients, HOP Energy specializes in premium heating oils, motor fuels, biofuels, natural gas, and a broad array of HVAC services, including the sale and installation of furnaces, boilers, heat pumps, and generators. The company also offers mobile fleet fueling, emergency response programs, and tailored payment options. HOP Energy serves a diverse service area, including Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, Pennsylvania, and Delaware.

Edgard Construction Materials LLC, established in 2018 and located in Edgard, Louisiana, specializes in supplying building materials for the construction industry in Southern Louisiana. The company offers a range of products, including clay material, river sand, and batch dirt, all of which are approved by the United States Army Corps of Engineers. In addition to these primary offerings, Edgard Construction Materials also provides various other fill soils, catering to the diverse needs of its customers in the region.

US Fitness Products provides fitness and gym equipment services to retail and commercial clients. Their services include home gym design, consumer financing, repair, preventative maintenance, commercial fitness solutions, commercial leasing, installation, and relocation.

Onelife Fitness provides sports training, weight loss, stress reduction, and sports training. Onelife Fitness gyms offer a solution.

Sage Metals Ltd. is a manufacturer of specialty metal products that caters to the North American markets, specifically in the electrical, power utility, industrial, and drainage sectors. Established over 30 years ago, the company has developed expertise in producing a range of metal products tailored to meet the needs of its diverse clientele.

Liposeuticals, Inc. is a specialty pharmaceuticals company dedicated to developing proprietary formulations of sterile injectable drugs, primarily targeting anesthesiology, oncology, and infectious diseases. Founded in 2012 and based in Monmouth Junction, New Jersey, the company specializes in non-water-soluble drugs and employs a patented drug reformulation technology that uses pure sugar-lipid polymers. This innovative approach enhances drug stability, extends shelf life, and reduces manufacturing costs while also addressing issues related to drug wastage and antibiotic resistance. Liposeuticals focuses on expediting the development and approval process through the 505(b)(2) pathway at the United States Food and Drug Administration (FDA), aiming to generate novel intellectual property and leverage regulatory exclusivity under the Hatch-Waxman Act. The company’s product offerings include well-known medications such as Diprivan, Taxotere, and Alimta, showcasing its commitment to improving the efficacy and safety of injectable therapies.

Barricaid is a medical device company that focuses on developing innovative solutions to prevent repeat disc herniation in patients who have undergone back surgery. The company's flagship product is a bone-anchored implant designed to reduce the likelihood of reherniation and the need for reoperation in cases involving large annular defects. This implant physically blocks the annulus at the surgical defect, enhancing the surgical outcome for patients at high risk of complications after lumbar discectomy. Composed of a titanium alloy, the device securely anchors into the vertebral body, either caudally or cranially, ensuring stability and effectiveness. By addressing the challenges associated with post-surgical recovery, Barricaid aims to improve patient outcomes and reduce the incidence of further surgeries related to sciatica.

Allecra Therapeutics GmbH, founded in 2013 and based in Weil am Rhein, Germany, focuses on developing innovative pharmaceuticals to address gram-negative multi-drug-resistant bacterial infections. The company is currently advancing a novel β-lactamase inhibitor through Phase 2 clinical development. This new treatment aims to counteract the resistance mechanisms of difficult-to-treat bacteria, which are particularly prevalent in hospital-acquired infections. By inhibiting β-lactamases, Allecra's approach directly targets the challenges posed by these resistant strains, providing healthcare providers with effective options to manage infections that may otherwise be inadequately treated. Situated in the BioValley Life Sciences region, Allecra Therapeutics is committed to delivering solutions that can save lives and improve patient outcomes in the face of rising antibiotic resistance.

BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing therapies for cancer treatment. The company's lead product, entinostat, is a class I HDAC inhibitor currently in Phase III clinical trials for advanced hormone receptor positive, HER2 negative breast cancer. Additionally, entinostat is being tested in combination with Keytruda and Tecentriq in Phase Ib/II trials for non-small cell lung cancer and metastatic breast cancer. Another significant candidate, SNDX-5613, is a selective inhibitor targeting the Menin-MLL interaction, undergoing Phase I/II trials for acute leukemias. The company is also developing SNDX-6352, a monoclonal antibody for chronic graft versus host disease, currently in Phase I/II trials. Syndax has established collaborations with major pharmaceutical companies and research organizations, enhancing its research and development capabilities. Founded in 2005, Syndax Pharmaceuticals aims to address critical needs in oncology through innovative therapeutic approaches.

Flamingo Island Flea Market is a prominent flea market located in Bonita Springs, Florida, covering 14.67 acres and featuring 81,152 square feet of open-air vendor space. It provides a diverse shopping experience with nearly 600 vendor booths offering a wide range of products, from new items to collectible goods. Conveniently situated near Interstate 75, the market attracts visitors looking for unique finds and bargains in a vibrant outdoor setting.

Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative solutions for eye care. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses that address the needs of the intraocular lens replacement market. Atia Vision's technology mimics the natural accommodation of the eye by utilizing the ciliary muscles, which allows for a full range of functional vision restoration for cataract patients. The accommodating intraocular lenses are designed to provide effective vision correction without the need for glasses, thereby improving patient outcomes and enhancing the overall quality of life for individuals with vision impairment.

FCA Packaging, established in 1985, specializes in the design and manufacture of highly customized, heavy-duty industrial packaging solutions tailored for leading original equipment manufacturers across various sectors, including aerospace, construction, and energy. The company offers a diverse range of products, including wood, steel, corrugated, and hybrid packaging, as well as expendable, reusable, and returnable options. FCA’s custom offerings encompass engineered skids, crates, pallets, boxes, and collapsible packaging, all designed to safeguard valuable inventory. In addition to its packaging products, FCA provides a suite of value-added services such as design, testing, manufacturing, container management, tracking, recycling management, and refurbishment. With a focus on just-in-time delivery, FCA Packaging delivers cost-effective solutions that enhance packaging protection and optimize operational efficiency for its clients.

Innovative Chemical Products, known as the ICP Group, is a manufacturer specializing in coatings, adhesives, sealants, and elastomers for various markets, including printing, graphic arts, construction, and industrial sectors. The company offers a range of chemical products tailored for commercial printing, labels, industrial coatings, transactional cards, and packaging needs. Additionally, it provides services related to building envelopes for residential, industrial, and commercial installations, as well as flooring and cementitious applications, aimed at enhancing, beautifying, and protecting various surfaces. With a focus on organic growth and strategic acquisitions, the ICP Group leverages its expertise and resources to establish a robust platform of specialty formulated products. The company emphasizes strong customer partnerships through a commitment to service, quality, and innovation, while benefiting from collaborative efforts in raw material purchasing and technological advancements.